The 41st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2023)

Lisbon, Portugal 08 May 2023 - 12 May 2023

Bivalent mRNA-1273.214 vaccine safe, immunogenic in children

13 Jun 2023 by

Interim results from the ongoing Study 306, a phase III open-label trial, show improved immunogenicity and safety of the bivalent Omicron-containing mRNA-1273.214 vaccine in children 6 months to 5 years of age, both as a primary series and a booster.

13 Jun 2023

Vaccination protects the young against COVID-19

31 May 2023 by

COVID-19 remains a global health concern, and children and adolescents are equally affected. In fact, COVID-19 hospitalization rates in children increased during the Omicron era. [MMWR 2022;71:271-278] In children aged 5–11 years who were hospitalized during the predominance of Omicron, nearly 90 percent were unvaccinated. [MMWR 2022;71:574-581]

31 May 2023

Maternal influenza vaccination reduces ILI risk in infants

27 May 2023 by

Administration of maternal influenza vaccine during the first- or second-trimester of pregnancy reduces the risk of influenza-like illness (ILI) in the offspring, according to a study presented at ESPID 2023.

27 May 2023

Paediatric TB care riddled with uncertainty, study says

25 May 2023 by

Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.

25 May 2023

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023 by

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

25 May 2023

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

25 May 2023 by

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.

25 May 2023

TAK-003 elicits cellular immune response against all dengue serotypes in paediatric cohort

24 May 2023 by

TAK-003, a live-attenuated, recombinant tetravalent dengue vaccine covering all four dengue virus (DENV) strains, elicited a cell-mediated immune (CMI) response in healthy children and adolescents aged 4–16 years, the phase II DEN-313 study has shown.

24 May 2023

Nirsevimab safe, effective against RSV lower respiratory tract infection

18 May 2023 by

A single dose of nirsevimab administered before or during the respiratory syncytial virus (RSV) season provides protection against RSV lower respiratory tract infection (LRTI) hospitalization and very severe infection in infants, according to the preliminary results of a clinical trial conducted in real-world settings.

18 May 2023

Dengue vaccine provides ample protection to children

17 May 2023 by

The dengue vaccine confers substantial protective benefit on children aged 10 to 15 years, reports a study in the Philippines, which was presented at the recent ESPID 2023.

17 May 2023